US equities
|
INTC
$66.10
▼-28.21%
AMZN
$239.55
▼-1.74%
MU
$890.12
▼-4.73%
NVDA
$206.34
▼-3.43%
SNDK
$1,193.90
▼-10.24%
GOOGL
$281.65
▼-0.76%
AMD
$513.21
▼-9.39%
SPCX
$139.27
▼-3.21%
INTC
$66.10
▼-28.21%
AMZN
$239.55
▼-1.74%
MU
$890.12
▼-4.73%
NVDA
$206.34
▼-3.43%
SNDK
$1,193.90
▼-10.24%
GOOGL
$281.65
▼-0.76%
AMD
$513.21
▼-9.39%
SPCX
$139.27
▼-3.21%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
NeoGenomics, Inc. - Common Stock
(NQ:
NEO
)
17.54
-0.39 (-2.18%)
Delayed Quote
Updated: 11:02 AM EDT, Oct 30, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about NeoGenomics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
What NeoGenomics (NEO) Said on Its Q3 Earnings Call
↗
October 29, 2026
NeoGenomics (NASDAQ:NEO) reported third-quarter revenue growth of 11% year over year, led by continued expansion in next-generation sequencing, or NGS, testing, while raising its full-year revenue and...
Via
MarketBeat
Topics
Earnings
NeoGenomics (NEO) Q3 2026 Earnings Call Transcript
↗
October 29, 2026
NGS revenue surged 29% as management raised full-year guidance.
Via
The Motley Fool
Topics
Earnings
NeoGenomics (NASDAQ:NEO) Posts In-Line Q3 Revenue and Above-Consensus EPS
↗
October 28, 2026
Via
Chartmill
NeoGenomics’s (NASDAQ:NEO) Q3 2026 sales beat estimates
October 28, 2026
Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) reported Q3 2026 results beating Wall Street’s revenue expectations, with revenue up 11.4% yea...
Via
StockStory
Topics
Earnings
NeoGenomics (NASDAQ:NEO): Quality Stock After Q2 Earnings Beat and Raised Guidance
↗
July 28, 2026
Via
Chartmill
Topics
Earnings
Earnings to watch: NeoGenomics (NEO) reports Q3 results tomorrow
October 26, 2026
Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) will be reporting earnings this Wednesday after market close. Here’s what investors should kno...
Via
StockStory
Topics
Artificial Intelligence
3 Small-Cap Stocks with Questionable Fundamentals
October 13, 2026
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in th...
Via
StockStory
Why NeoGenomics (NEO) Stock Is Up Today
October 06, 2026
What Happened? Shares of oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) jumped 3.6% in the pre-market session after the company announced an ...
Via
StockStory
Topics
Regulatory Compliance
3 Healthcare Stocks We’re Skeptical Of
September 23, 2026
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from eleva...
Via
StockStory
3 Reasons NEO is Risky and 1 Stock to Buy Instead
September 22, 2026
What a time it’s been for NeoGenomics. In the past six months alone, the company’s stock price has increased by a massive 138%, reaching $19.30 per share. Th...
Via
StockStory
Topics
Bankruptcy
Supply Chain
NeoGenomics Highlights NGS, MRD Growth Strategy at Morgan Stanley Conference
↗
September 20, 2026
NeoGenomics (NASDAQ:NEO) executives outlined the company’s strategy to expand its role in community-based precision oncology, emphasizing growth in next-generation sequencing, minimal residual disease...
Via
MarketBeat
1 Unpopular Stock That Deserves a Second Chance and 2 We Turn Down
September 18, 2026
Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad t...
Via
StockStory
Topics
Economy
A Look Back at Testing & Diagnostics Services Stocks’ Q2 Earnings: NeoGenomics (NASDAQ:NEO) Vs The Rest Of The Pack
September 10, 2026
Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at NeoGenomics (NASDAQ:NEO) and ...
Via
StockStory
3 Unprofitable Stocks Walking a Fine Line
August 21, 2026
Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, th...
Via
StockStory
3 Stocks Under $50 with Open Questions
August 06, 2026
Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However...
Via
StockStory
3 Healthcare Stocks with Questionable Fundamentals
August 03, 2026
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have not on...
Via
StockStory
Why NeoGenomics (NEO) Stock Is Up Today
July 29, 2026
What Happened? Shares of oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) jumped 15.8% in the afternoon session after the company reported seco...
Via
StockStory
3 of Wall Street’s Favorite Stocks with Questionable Fundamentals
July 29, 2026
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remember...
Via
StockStory
NeoGenomics Q2 Earnings Call Highlights
↗
July 28, 2026
NeoGenomics (NASDAQ:NEO) raised its full-year 2026 revenue and adjusted EBITDA guidance after reporting second-quarter revenue growth that exceeded its prior outlook, led by higher-value clinical...
Via
MarketBeat
Topics
Earnings
NeoGenomics’s (NASDAQ:NEO) Q2 CY2026: Beats On Revenue
July 28, 2026
Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 11.2% year on...
Via
StockStory
NeoGenomics (NEO) Q2 Earnings Report Preview: What To Look For
July 26, 2026
Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) will be announcing earnings results this Tuesday afternoon. Here’s what you need to know. NeoG...
Via
StockStory
Topics
Artificial Intelligence
1 Momentum Stock with Solid Fundamentals and 2 We Avoid
July 23, 2026
The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically signals strong business execution, pos...
Via
StockStory
3 Small-Cap Stocks with Questionable Fundamentals
July 15, 2026
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and...
Via
StockStory
NeoGenomics (NEO) Stock Trades Up, Here Is Why
July 09, 2026
What Happened? Shares of oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) jumped 3.4% in the afternoon session after the company announced the ...
Via
StockStory
Topics
Intellectual Property
Lawsuit
A Look Back at Testing & Diagnostics Services Stocks’ Q1 Earnings: NeoGenomics (NASDAQ:NEO) Vs The Rest Of The Pack
June 25, 2026
Looking back on testing & diagnostics services stocks’ Q1 earnings, we examine this quarter’s best and worst performers, including NeoGenomics (NASDAQ:NEO) a...
Via
StockStory
1 Unprofitable Stock for Long-Term Investors and 2 Facing Headwinds
June 19, 2026
Running at a loss can be a red flag. Many of these businesses face mounting challenges as competition increases and funding becomes harder to secure. Unprofi...
Via
StockStory
NeoGenomics and Charles River Laboratories Shares Plummet, What You Need To Know
May 13, 2026
What Happened? A number of stocks fell in the afternoon session after the April PPI report showed wholesale inflation accelerating to 6% annually, with servi...
Via
StockStory
Topics
Economy
3 Russell 2000 Stocks We’re Skeptical Of
May 08, 2026
The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However,...
Via
StockStory
3 Reasons NEO is Risky and 1 Stock to Buy Instead
May 06, 2026
Over the past six months, NeoGenomics’s shares (currently trading at $9.01) have posted a disappointing 13.4% loss, well below the S&P 500’s 7.1% gain. This ...
Via
StockStory
Topics
Bankruptcy
Stocks
Supply Chain
5 Insightful Analyst Questions From NeoGenomics’s Q1 Earnings Call
May 05, 2026
NeoGenomics delivered an 11% year-over-year revenue increase in Q1, exceeding Wall Street’s expectations for the period. Management attributed this performan...
Via
StockStory
Topics
Earnings
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
